Additionally, in vivo, letrozole (ARO inhibitor) improved pembrolizumab efficacy, while in NSCLC patients, ERα was a predictive response factor to pembrolizumab, even stronger than sex and PD-L1 levels (92). Here, CD274 is linked to non-small cell lung carcinoma.